Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

hich should not be given to healthy volunteers, this evaluation is being done in previously untreated elderly patients with de novo poor-risk AML who receive Cloretazine(R) (VNP40101M) therapy.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. A Phase II trial of Cloretazine(R) (VNP40101M) in small cell lung cancer is also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and f
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015 Research and ... the "Radiology Information Systems Market by Type, Deployment ... & Forecast to 2019" report to their offering. ... is estimated at $501.1 Million 2014, and is projected ... of 7.6% from 2014 to 2019. ...
(Date:9/3/2015)... YORK , Sept. 3, 2015  The findings ... are raising disturbing questions about the company,s handling of ... LLP reports.  On September 2 nd , part ... 300 adverse events, including at least 27 fatalities, have ... disclosed a confidential study commissioned by C.R. Bard in ...
(Date:9/3/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/84p6xc/investigation ... Report on China,s Bromhexine Market, 2010-2019" report to ... incidence of respiratory disease keeps growing and so does ... derivative of vasicine, is a mucolytic agent used in ... viscid or excessive mucus. It can make the phlegm ...
Breaking Medicine Technology:Radiology Information Systems Market Report 2015 - Global Trends & Forecast to 2019 for the $700+ Million Industry 2Radiology Information Systems Market Report 2015 - Global Trends & Forecast to 2019 for the $700+ Million Industry 3IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 2IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 3China Bromhexine Market Report 2015-2019 2
... Oct. 14, 2011 Pregis Corporation, a leading ... products and specialty packaging solutions, announced today that ... to sell its Kobusch-Sengewald business unit to Sun ... adviser to Sun Capital Partners, Inc., for gross ...
... Mass., Oct. 14, 2011 Boston Scientific Corporation (NYSE: ... Medical Device Regulatory Improvement Act, sponsored by Sen. Amy ... and Michael Bennet (D-CO).  The legislation is intended to ... regulatory delays and help new medical technologies safely and ...
Cached Medicine Technology:Pregis Announces Sale of Kobusch-Sengewald Business to an Affiliate of Sun European Partners 2Pregis Announces Sale of Kobusch-Sengewald Business to an Affiliate of Sun European Partners 3
(Date:9/3/2015)... ... September 03, 2015 , ... NanoCytomics LLC today announced ... company that will bring low-cost cancer pre-screening tests to primary care physicians in ... automated technology platform detects and measures cellular changes at the nanoscale level. The ...
(Date:9/3/2015)... OR (PRWEB) , ... September 03, 2015 , ... ... named the academic partner for the Academy of Integrative Health & Medicine (AIHM) ... under the direction of Tieraona Low Dog, MD, an internationally renowned educator, physician ...
(Date:9/3/2015)... ... September 03, 2015 , ... The Beryl Institute ... 2016, to be held April 13-15 at Sheraton Hotel in Dallas, Texas. Patient ... the collective voices of healthcare leaders, staff, physicians, patients and families across the ...
(Date:9/3/2015)... ... September 03, 2015 , ... Topical BioMedics, Inc., hosted Amsterdam ... his six-month, 10,000 mile journey from Santiago, Chile to Times Square and then ... “Connecting Las Americas” project—Max crossed six countries in 168 days on his 39-year-old ...
(Date:9/3/2015)... ... September 03, 2015 , ... BedJet released a new ... v2, for pre-order on Kickstarter. Today the BedJet v2 pre-order campaign blazed ... top 0.1% most successful campaigns ever on crowdfunding giant Kickstarter. , Simple to use ...
Breaking Medicine News(10 mins):Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 2Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 3Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 2Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 3Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 2Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 3Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 2Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 3Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 4Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 5Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 6Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 2Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 3
... Vereen Issues a Call-to-Action for People with Diabetes to ... Diabetes Today, BRIDGEWATER, N.J., Sept. 24 Tony,Award-winning ... a world leader in diabetes care, to launch Take ... to educate,people living with diabetes about their condition. Since ...
... Age 55 and Over to Know the Signs,of ... Suspected, WASHINGTON, D.C., Sept. 24 Despite ... detection, there are,striking differences between intentions and actual ... adults age 55 and over titled, "Alzheimer,s,Disease: Current ...
... Launch of the Disposable flexfit (TM) Breaks down Longstanding Barriers to ... ... N.J., Sept. 24 Songbird Hearing, Inc.,today introduces a unique option ... that 55 million Americans currently,experience some degree of hearing loss, while ...
... Hospital Assets,Patient Care to Remain Uninterrupted At HPA Hospitals, ... America,("HPA" or "the Company") announced today that it and ... Chapter 11,of the U.S. Bankruptcy Code. The filings do ... the HPA system, which continue to operate as usual.,The ...
... The 2008 Compensation Data survey results found that 67.3 percent ... and their family. , ... Kansas ... increases, employers and employees continue to see high health insurance ...
... Drug Administration,s (FDA,s) plan to list those drugs whose safety is ... drug companies, physicians, and patients. , ... Horsham, PA ... the Food and Drug Administration,s (FDA,s) plan to list those drugs ...
Cached Medicine News:Health News:Ben Vereen, Tony Award-Winning Actor, Strives to Raise Awareness of Diabetes and Treatment 2Health News:Ben Vereen, Tony Award-Winning Actor, Strives to Raise Awareness of Diabetes and Treatment 3Health News:New Alzheimer's Disease Survey Reveals Disparities Between Beliefs and Behavior in Pursuing Diagnosis 2Health News:New Alzheimer's Disease Survey Reveals Disparities Between Beliefs and Behavior in Pursuing Diagnosis 3Health News:New Alzheimer's Disease Survey Reveals Disparities Between Beliefs and Behavior in Pursuing Diagnosis 4Health News:New Alzheimer's Disease Survey Reveals Disparities Between Beliefs and Behavior in Pursuing Diagnosis 5Health News:Songbird Hearing Provides Revolutionary Alternative for Those Dealing With Hearing Loss 2Health News:Songbird Hearing Provides Revolutionary Alternative for Those Dealing With Hearing Loss 3Health News:Corporate Parent Hospital Partners of America Files Voluntary Chapter 11 Petition; Filings do not Include any Hospital Facilities 2Health News:Health Insurance Premium Costs High for Employers and Employees 2Health News:DIA/FDA/PhRMA Drug Safety Conference: Planning the Lifecycle of Safety Evaluation 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: